Project Grant R41HG014125
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$215K
Federal Agency
National Human Genome Research Institute
Federal Grant Program
93.172
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research CFDA program (93.172), provides $406,500 to Directseq Biosciences, Inc. to advance next-generation mass spectrometry-based sequencing (NGMS-SEQ) methods. The primary objectives are to 1) develop high-throughput NGMS-SEQ techniques for direct sequencing of transfer RNA (tRNA) samples, including physiologically relevant ones, and 2) enhance technologies to quantitatively...
This federal Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), aims to develop SPINSEQ, an innovative RNA sequencing platform that can accurately detect and quantify critical RNA modifications. The $383,482 award, granted on June 6, 2025, will fund the Phase I development and optimization of the SPINSEQ technology, which seeks to overcome the limitations of existing RNA sequencing methods by preserving RNA...
The National Human Genome Research Institute (NHGRI) awarded a $594,501 Project Grant (CFDA 93.172 - Human Genome Research) to Cold Spring Harbor Laboratory to develop a unified probabilistic model and software implementation for analyzing nascent RNA sequencing data. The project aims to create powerful computational tools that can accelerate transcriptional research by enabling the estimation of transcriptional rates directly from nascent RNA sequencing data, with applications in areas such...
This Project Grant award of $350,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop innovative technology capable of high-accuracy sequencing of the RNA modifications pseudouridine (Ψ) and N6-methyladenosine (m6A). The project is a collaborative effort between academia and industry, led by Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The key objectives are...
The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $384,418 Project Grant to Xgenomes Corp. on September 25, 2024 to develop a revolutionary DNA sequencing platform. The project aims to create a super-resolution single-molecule sequencing technology that can read short sequence "words" rather than individual nucleotides, enabling one or more orders of magnitude improvements in accuracy and cost over...
The National Human Genome Research Institute (NHGRI), under the Federal Grant Program "Human Genome Research" (CFDA 93.172), awarded a $407,291 Phase I Small Business Innovation Research (SBIR) grant to Electronic Biosciences, Inc. to develop a nanopore-based protein sequencing platform. The project aims to create a high-accuracy, label-free nanopore reader capable of direct, single-molecule protein sequencing. This novel technology would enable proteome-wide profiling, biomarker...
The federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,507,500 to the University of Massachusetts Medical School (UMass Medical) to expand the capabilities of third-generation DNA/RNA sequencing technologies. The project aims to generate rapid and cost-effective training libraries to allow for direct detection of common DNA damage and RNA modifications, enabling innovative...
The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $1,234,692 Project Grant to Evizia Inc. for the development of a novel instrument and consumables for quality control in next-generation sequencing (NGS). Evizia's PRECYSE system utilizes high-speed atomic force microscopy to provide improved QC metrics and sensitivity for DNA sample analysis compared to traditional gel electrophoresis methods. The system enables...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,445 to Endura Therapeutics Inc. aims to develop a next-generation sequencing platform for discovering small molecules that target RNA. The project seeks to demonstrate that small molecules binding to messenger RNA can modulate protein expression in cells and to create a high-throughput screening method to identify such molecules and their optimal RNA targets. The research...
The National Institute of General Medical Sciences (NIGMS) awarded a $445,000 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to The Children's Hospital of Philadelphia (CHOP) to develop long-read RNA sequencing technologies and apply them to advancing genomic medicine. The central objective is to harness long-read transcriptomics to elucidate transcriptome complexity and identify therapeutic targets for rare and complex diseases. The 5-year project aims to: 1) develop...